Novartis Healthcare Philippines, Inc.
- World Health Organization (WHO)
- Department of Health (WHO)
- Local Government Units (LGUs)
- Malaria advocacy groups
- Pilipinas Shell Foundation, Inc.
In 2001, research-based Swiss healthcare company Novartis and the WHO launched a groundbreaking 10-year alliance to provide a breakthrough medicine against malaria—without profit—for use by public health systems in developing countries. Under the program, Novartis provides our anti-malaria drug Coartem® (artemether+lumefantrine) at cost to the WHO, which distributes the drug through governments of malaria-endemic countries. A decade after its launch, the Novartis Malaria Initiative has become the largest access-to-medicines program for the developing world and is acclaimed as one of the most successful access initiatives to date. Since 2001, Novartis has provided over 400 million drug treatments in more than 60 malaria-endemic countries, saving an estimated 1 million lives, mostly infants and children. Since 2002 when the Novartis Malaria Initiative was first implemented in the country, Novartis has provided over 172,260 anti-malaria drug treatments to Filipino patients at cost, saving an estimated 43,000 lives. The development of Coartem® and its access program was initiated in response to MDG target no. 8, which aims to provide access to affordable essential drugs for neglected tropical diseases endemic in developing countries.
Saan maaaring pumunta?
Municipal or City Health Center.
Saan tatawag para sa mga katanungan tungkol sa programa?
Patients can get in touch with their Municipal or City Health Center.